276 results on '"Thrombin drug effects"'
Search Results
2. A correlation of thrombin generation assay and clot waveform analysis in patients on warfarin.
- Author
-
Cheong MA, Tan CW, Wong WH, Kong MC, See E, Yeang SH, Koh SK, Shim YT, Lee LH, and Ng HJ
- Subjects
- Humans, Middle Aged, Prospective Studies, Warfarin pharmacology, Blood Coagulation drug effects, Blood Coagulation Tests methods, Thrombin drug effects, Warfarin therapeutic use
- Abstract
Objectives: Thrombin generation assays and activated partial thromboplastin time (aPTT)-based clot waveform analysis (CWA), are some examples of global coagulation assays. Each modality evaluates different aspects of the clot forming process to globally define haemostasis with exclusive measurement parameters. Data on CWA are emerging, but its performance against other haemostatic assays is yet to be ascertained. This study evaluates the correlation between aPTT-based CWA and CAT parameters across a range of INR in warfarin-treated patients., Patients/methods: A prospective study consisting of patients on warfarin anticoagulation with varying INR levels. CWA and CAT were performed for the study subjects., Results: 54 samples were included covering an INR range from 1.33-6.89, with a mean of 4.31 +/- 1.13. For CAT parameters, endogenous thrombin potential (ETP) and peak thrombin were assessed. Both unadjusted and adjusted (adjusted for final plateau transmittance) aPTT-based CWA were evaluated for parameters min1 (maximum velocity), min2 (maximum acceleration) and max2 (maximum deceleration). Peak thrombin showed significant correlation with all CWA parameters (min1: r = 0.435, P <0.001; min2: r = 0.485, P <0.001; max2: r = 0.578, P <0.001; adjusted min1: r = 0.734, P <0.001, adjusted min2: r = 0.693, P <0.001; adjusted max2: r = 0.751, P <0.001). ETP correlated significantly with all CWA parameters except unadjusted min1 (min1: r = 0.235, P = 0.087; min2: r = 0.326, P = 0.016; max2: r = 0.437, P <0.001; adjusted min1: r = 0.610, P <0.001, adjusted min2: r = 0.563, P <0.001; adjusted max2: r = 0.642, P <0.001)., Conclusion: We demonstrated a modest correlation between CAT and CWA parameters. Adjusted CWA improved this correlation. These findings provide additional understanding of CWA and it's role in the evaluation of global haemostatic function.
- Published
- 2022
- Full Text
- View/download PDF
3. Protective role of serpina3c as a novel thrombin inhibitor against atherosclerosis in mice.
- Author
-
Qian LL, Ji JJ, Guo JQ, Wu YP, Ma GS, and Yao YY
- Subjects
- Animals, Antithrombins pharmacology, Aorta, Apolipoproteins E deficiency, Atherosclerosis pathology, Cells, Cultured, Dabigatran pharmacology, Diet, High-Fat, Male, Mice, Inbred C57BL, Mice, Knockout, Neointima, Plaque, Atherosclerotic metabolism, Serpins genetics, Signal Transduction, Mice, Atherosclerosis metabolism, Serpins pharmacology, Thrombin drug effects
- Abstract
Abnormal vascular smooth muscle cell (VSMC) proliferation is a critical step in the development of atherosclerosis. Serpina3c is a serine protease inhibitor (serpin) that plays a key role in metabolic diseases. The present study aimed to investigate the role of serpina3c in atherosclerosis and regulation of VSMC proliferation and possible mechanisms. Serpina3c is down-regulated during high-fat diet (HFD)-induced atherosclerosis. An Apoe-/-/serpina3c-/--double-knockout mouse model was used to determine the role of serpina3c in atherosclerosis after HFD for 12 weeks. Compared with Apoe-/- mice, the Apoe-/-/serpina3c-/- mice developed more severe atherosclerosis, and the number of VSMCs and macrophages in aortic plaques was significantly increased. The present study revealed serpina3c as a novel thrombin inhibitor that suppressed thrombin activity. In circulating plasma, thrombin activity was high in the Apoe-/-/serpina3c-/- mice, compared with Apoe-/- mice. Immunofluorescence staining showed thrombin and serpina3c colocalization in the liver and aortic cusp. In addition, inhibition of thrombin by dabigatran in serpina3c-/- mice reduced neointima lesion formation due to partial carotid artery ligation. Moreover, an in vitro study confirmed that thrombin activity was also decreased by serpina3c protein, supernatant and cell lysate that overexpressed serpina3c. The results of experiments showed that serpina3c negatively regulated VSMC proliferation in culture. The possible mechanism may involve serpina3c inhibition of ERK1/2 and JNK signaling in thrombin/PAR-1 system-mediated VSMC proliferation. Our results highlight a protective role for serpina3c as a novel thrombin inhibitor in the development of atherosclerosis, with serpina3c conferring protection through the thrombin/PAR-1 system to negatively regulate VSMC proliferation through ERK1/2 and JNK signaling., (© 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.)
- Published
- 2021
- Full Text
- View/download PDF
4. Thrombin Signaling Contributes to High Glucose-Induced Injury of Human Brain Microvascular Endothelial Cells.
- Author
-
Vittal Rao H, Bihaqi SW, Iannucci J, Sen A, and Grammas P
- Subjects
- Alzheimer Disease epidemiology, Alzheimer Disease metabolism, Brain drug effects, Brain metabolism, Cyclic AMP Response Element-Binding Protein drug effects, Cyclic AMP Response Element-Binding Protein metabolism, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 metabolism, Endothelial Cells drug effects, Endothelium, Vascular drug effects, Endothelium, Vascular metabolism, Humans, Inflammation, Interleukin-6 metabolism, Matrix Metalloproteinase 2 drug effects, Matrix Metalloproteinase 2 metabolism, Matrix Metalloproteinase 9 drug effects, Matrix Metalloproteinase 9 metabolism, Microvessels cytology, NADPH Oxidase 4 drug effects, NADPH Oxidase 4 metabolism, Nitric Oxide Synthase Type II drug effects, Nitric Oxide Synthase Type II metabolism, Oxidative Stress drug effects, Thrombin drug effects, Thrombin pharmacology, Tumor Necrosis Factor-alpha drug effects, Tumor Necrosis Factor-alpha metabolism, Up-Regulation, p38 Mitogen-Activated Protein Kinases drug effects, p38 Mitogen-Activated Protein Kinases metabolism, Antithrombins pharmacology, Brain blood supply, Dabigatran pharmacology, Endothelial Cells metabolism, Endothelium, Vascular physiopathology, Glucose toxicity, Thrombin metabolism
- Abstract
Background: Diabetes is one of the strongest disease-related risk factors for Alzheimer's disease (AD). In diabetics, hyperglycemia-induced microvascular complications are the major cause of end-organ injury, contributing to morbidity and mortality. Microvascular pathology is also an important and early feature of AD. The cerebral microvasculature may be a point of convergence of both diseases. Several lines of evidence also implicate thrombin in AD as well as in diabetes., Objective: Our objective was to investigate the role of thrombin in glucose-induced brain microvascular endothelial injury., Methods: Cultured Human brain microvascular endothelial cells (HBMVECs) were treated with 30 mM glucose±100 nM thrombin and±250 nM Dabigatran or inhibitors of PAR1, p38MAPK, MMP2, or MMP9. Cytotoxicity and thrombin activity assays on supernatants and western blotting for protein expression in lysates were performed., Results: reatment of HBMVECs with 30 mM glucose increased thrombin activity and expression of inflammatory proteins TNFα, IL-6, and MMPs 2 and 9; this elevation was reduced by the thrombin inhibitor dabigatran. Direct treatment of brain endothelial cells with thrombin upregulated p38MAPK and CREB, and induced TNFα, IL6, MMP2, and MMP9 as well as oxidative stress proteins NOX4 and iNOS. Inhibition of thrombin, thrombin receptor PAR1 or p38MAPK decrease expression of inflammatory and oxidative stress proteins, implying that thrombin may play a central role in glucose-induced endothelial injury., Conclusion: Since preventing brain endothelial injury would preserve blood-brain barrier integrity, prevent neuroinflammation, and retain intact functioning of the neurovascular unit, inhibiting thrombin, or its downstream signaling effectors, could be a therapeutic strategy for mitigating diabetes-induced dementia.
- Published
- 2021
- Full Text
- View/download PDF
5. Effect of emicizumab on thrombin generation: A case report of breakthrough bleeding during emicizumab treatment.
- Author
-
Valke LLFG, Beckers EAM, Blijlevens NMA, van Heerde WL, and Schols SEM
- Subjects
- Antibodies, Bispecific pharmacology, Antibodies, Monoclonal, Humanized pharmacology, Female, Humans, Middle Aged, Antibodies, Bispecific therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Thrombin drug effects
- Published
- 2020
- Full Text
- View/download PDF
6. A novel mechanism of ACE inhibition-associated enhanced platelet reactivity: disproof of the ARB-MI paradox?
- Author
-
Helten C, Mourikis P, Dannenberg L, M'Pembele R, Trojovsky K, Ayhan A, Kohlmorgen C, Grandoch M, Levkau B, Veulemans V, Petzold T, Hohlfeld T, Kelm M, Zeus T, and Polzin A
- Subjects
- Aged, Aged, 80 and over, Blood Platelets metabolism, Female, Flow Cytometry, Humans, Male, Middle Aged, Pilot Projects, Platelet Aggregation drug effects, Platelet Function Tests, Renin-Angiotensin System drug effects, Thrombin metabolism, Time Factors, Angiotensin Receptor Antagonists pharmacology, Angiotensin-Converting Enzyme Inhibitors pharmacology, Blood Platelets drug effects, Thrombin drug effects
- Abstract
Purpose: ACE inhibitors (ACEI) and angiotensin II receptor blockers (ARB) are important drugs in cardiovascular disease. However, little is known about which of these drug class is to be preferred. First analyses show that the blockade of the renin-angiotensin-aldosterone system (RAAS) influences platelet reactivity. Therefore, we evaluated the effects of ACEI and ARB on platelet reactivity and thrombin generation., Methods: We conducted a time series analysis in 34 patients. We performed light transmission aggregometry (LTA) to evaluate platelet reactivity. Results are given as maximum of aggregation (MoA). Thrombin generation was measured as endogenous thrombin potential (ETP) via calibrated automated thrombogram. Flow cytometry was used to analyze protease-activated receptor (PAR)-1 expression., Results: ACEI treatment significantly increased platelet reactivity already 4 h after initiation of treatment (prior vs. 4 h post ACEI: MoA 41.9 ± 16.2% vs. 55.2 ± 16.7%; p = 0.003). After switching from ACEI to ARB treatment, platelet reactivity decreased significantly (3 months after switching: MoA 34.7 ± 20.9%; p = 0.03). ACEI reduced endogenous thrombin potential significantly from before to 3 months after ACEI (ETP 1527 ± 437 nM × min vs. 1088 ± 631 nM × min; p = 0.025). Platelet thrombin receptor (PAR1) expression increased from 37.38 ± 10.97% before to 49.53 ± 6.04% after ACEI treatment (p = 0.036)., Conclusion: ACEI enhanced platelet reactivity. This can be reversed by changing to ARB. The mechanism behind RAAS influencing platelet function seems to be associated with PAR-1 expression.
- Published
- 2020
- Full Text
- View/download PDF
7. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: Study in plasma and cell-based models.
- Author
-
Ammollo CT, Semeraro F, Vitulli A, Dirienzo L, Mezzasoma AM, Semeraro N, Gresele P, and Colucci M
- Subjects
- Carboxypeptidase B2 drug effects, Carboxypeptidase B2 metabolism, Carboxypeptidase B2 pharmacology, Coagulants pharmacology, Coagulants therapeutic use, Combined Modality Therapy, Endothelial Cells drug effects, Endothelial Cells metabolism, Factor VIII therapeutic use, Fibrinolysis drug effects, Hemophilia A blood, Hemostasis drug effects, Hemostasis physiology, Humans, Immunoglobulin G metabolism, Kinetics, Plasma metabolism, Protein C metabolism, Thrombin drug effects, Thrombin metabolism, Thrombomodulin metabolism, Thromboplastin metabolism, Treatment Outcome, von Willebrand Factor therapeutic use, Factor VIII pharmacology, Hemophilia A drug therapy, von Willebrand Factor pharmacology
- Abstract
Introduction: Plasma-derived FVIII/VWF complex was reported to be less sensitive to inhibitors than FVIII preparations devoid of VWF., Aim: To compare the efficacy of FVIII/VWF complex (Fanhdi) and five different VWF-free FVIII preparations in restoring thrombin generation and activation of thrombin-activatable fibrinolysis inhibitor (TAFI) in haemophilic plasma, with and without inhibitor, and in cell-based models., Methods: Experiments were performed in haemophilic plasma supplemented with inhibitory IgG or in plasma samples obtained from haemophilia A patients without (n = 11) and with inhibitor (n = 12). Thrombin generation was evaluated by calibrated automated thrombography (CAT) under standard conditions, in the presence of activated protein C (APC) or thrombomodulin (TM), and in cell-based models including endothelial cells, either alone or in combination with platelets or tissue factor-expressing blood mononuclear cells. The kinetics of TAFI activation was determined by a two-stage functional assay in the absence and in the presence of APC., Results: In haemophilic plasma without inhibitor, Fanhdi enhanced thrombin generation and TAFI activation as well as recombinant (2nd-4th generation) and plasma-derived FVIII preparations devoid of VWF. On the contrary, in plasma with inhibitor, Fanhdi displayed a greater ability to restore thrombin generation and TAFI activation under all tested conditions. Notably, in cell-based models including endothelial cells, Fanhdi proved more efficient than all other preparations in improving thrombin generation even in the absence of inhibitor., Conclusion: The greater pro-haemostatic activity of FVIII/VWF complex, either in haemophilic plasma with inhibitor or in the presence of endothelial cells, may offer therapeutic advantages., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
8. Kaolin, used to trigger coagulation in thrombin generation test, increases sensitivity of the method in hemophilia patients.
- Author
-
Gribkova IV, Galstyan GM, Polyanskaya TY, and Sinauridze EI
- Subjects
- Adult, Antidiarrheals pharmacology, Female, Hemophilia A, Humans, Kaolin pharmacology, Male, Middle Aged, Young Adult, Antidiarrheals therapeutic use, Kaolin therapeutic use, Thrombin drug effects
- Abstract
: Thrombin generation test (TGT) is well established tool to research blood coagulation in plasma of hemophilia patients. Traditionally coagulation in this test is triggered by a tissue factor (TF), an extrinsic coagulation pathway activator. However, it is known that disorders of the intrinsic pathway are most important for coagulation in hemophilia. In this study, we hypothesized that triggering coagulation via the intrinsic pathway could increase a sensitivity of the TGT to monitor hemophilia treatment. The aim of this study was to compare thrombin generation in hemophilia A patients with inhibitors to factor VIII before and after infusion of bypassing agent [recombinant-activated factor VIIa (rVIIa)] using standard activation of coagulation by TF or by kaolin, an activator of coagulation by intrinsic pathway. Endogenous thrombin potential (ETP) in nine patients was measured. ETP before (ETP0) and 60 min after rVIIa infusion (ETP60) were compared. It was shown that ETP0 and ETP60 were significantly different when using any coagulation activator (paired Student's t test, P = 0.017 and 3.7 × 10 for clotting activation by TF and kaolin, respectively). The ratios of ETP60/ETP0 were 1.2 ± 0.2 or 30.0 ± 22.4 (mean ± SD, n = 9) for coagulation activated by TF or kaolin, respectively, and were significantly different (paired Student's t test, P < 0.005). The TGT clearly distinguished between ETP0 and ETP60 in the case of any coagulation activator, but ETP increasing after rVIIa infusion was significantly higher when activated with kaolin. This provided increased sensitivity of this method for monitoring hemophilia therapy.
- Published
- 2020
- Full Text
- View/download PDF
9. Concomitant assessment of rivaroxaban concentration and its impact on thrombin generation.
- Author
-
Bloemen S, Zwaveling S, Mullier F, and Douxfils J
- Subjects
- Factor Xa Inhibitors pharmacology, Female, Humans, Male, Rivaroxaban pharmacology, Factor Xa Inhibitors therapeutic use, Rivaroxaban therapeutic use, Thrombin drug effects
- Abstract
Background: Reliable assays to measure direct oral anticoagulant (DOAC) levels and their activity in critical situations are needed. Drug levels alone are not representative of the effect of DOACs on an individual's coagulation. We developed a technique that provides direct assessment of the global effect of rivaroxaban on the individual's coagulation in addition to plasma concentrations., Methods: DOAC concentrations were determined in fifty patients using rivaroxaban, with the new assay, Xross-CAT. The effect of rivaroxaban on coagulation (activity) was measured with thrombin generation (TG) in platelet poor plasma using 5 pM tissue factor on the same device. The levels were validated with the Biophen DiXal assay. The prothrombin time (PT) and dilute Russell viper venom time (dRVVT) were performed to estimate the effect on coagulation., Results: The variability of Xross-CAT was below 12%. Xross-CAT correlates well with Biophen DiXaI (r
s = 0.885). The bias, determined by Bland-Altman analysis, was 4.9% and the Passing-Bablok equation was y = 1.1x - 2.1. The correlation of plasma levels with TG was moderate (ETP rs = -0.548; Peak rs = -0.559), as for the PT (rs = 0.739) and the dRVVT (rs = 0.692)., Conclusions: Xross-CAT shows a good correlation with Biophen DiXaI that was previously confirmed to accurately assess rivaroxaban levels. Bleeding and thrombotic complications are not necessarily associated with drug levels and could be influenced by concomitant risk factors. The main benefit of Xross-CAT is that it can be performed simultaneously with thrombin generation, providing an overview of the global anticoagulation status of a patient in relation to circulating DOAC levels., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
10. DNA Aptamers to Thrombin Exosite I. Structure-Function Relationships and Antithrombotic Effects.
- Author
-
Spiridonova VA, Novikova TM, Sizov VA, Shashkovskaya VS, Titaeva EV, Dobrovolsky AB, Zharikova EB, and Mazurov AV
- Subjects
- Aptamers, Nucleotide chemistry, Binding Sites, Blood Coagulation Tests, Humans, Platelet Aggregation drug effects, Structure-Activity Relationship, Antithrombins pharmacology, Aptamers, Nucleotide pharmacology, Thrombin drug effects
- Abstract
DNA aptamers (oligonucleotides) interacting with thrombin exosite I contain G-quadruplex, two T-T, and one T-G-T loops in their structure. They prevent exosite I binding with fibrinogen and thrombin receptors on platelet surface, thereby suppressing thrombin-stimulated formation of fibrin from fibrinogen and platelet aggregation. Earlier, we synthesized original antithrombin aptamer RE31 (5'-GTGACGTAGGTTGGTGTGGTTGGGGCGTCAC-3') that contained (in addition to G-quadruplex) a hinge region connected to six pairs of complementary bases (duplex region). In this study, we compared properties of RE31 aptamer and its analogues containing varying number of bases in the duplex region and nucleotide insertions in the hinge region. Reduction in the number of nucleotides in the duplex region by 1 to 4 pairs (in comparison with RE31 aptamer) resulted in the decrease of the structural stability of aptamers (manifested as lower melting temperatures) and their ability to inhibit thrombin-stimulated fibrin formation in human blood plasma in tests of thrombin, prothrombin, and activated partial thromboplastin times. However, an increase in the number of bases by 1 to 2 pairs did not cause significant changes in the stability and antithrombin activity of the aptamers. Insertions into the hinge region of RE31 aptamer decreased its antithrombin activity. Investigation of RE31 antithrombotic properties demonstrated that RE31 (i) slowed down thrombin formation in human blood plasma (thrombin generation test), (ii) accelerated lysis of fibrin clot by tissue plasminogen activator in in vitro model, and (iii) suppressed arterial thrombosis in in vivo model. Based on the obtained data, RE31 aptamer can be considered as a potentially effective antithrombotic compound.
- Published
- 2019
- Full Text
- View/download PDF
11. Nonhemostatic Activities of Factor Xa: Are There Pleiotropic Effects of Anti-FXa Direct Oral Anticoagulants?
- Author
-
Papadaki S and Tselepis AD
- Subjects
- Administration, Oral, Animals, Anticoagulants administration & dosage, Factor Xa Inhibitors administration & dosage, Humans, Thrombin drug effects, Anticoagulants therapeutic use, Blood Coagulation drug effects, Factor Xa drug effects, Factor Xa Inhibitors therapeutic use
- Abstract
Factor Xa (FXa) is the key serine protease of the coagulation cascade as it is the point of convergence of the intrinsic and extrinsic pathways, leading to the formation of thrombin. Factor Xa is an established target of anticoagulation therapy, due to its central role in coagulation. Over the past years, several direct oral anticoagulants (DOACs) targeting FXa have been developed. Rivaroxaban, apixaban, and edoxaban are used in clinical practice for prevention and treatment of thrombotic diseases. Increasing evidence suggests that FXa exerts nonhemostatic cellular effects that are mediated mainly through protease-activated receptors-1 and -2 and are involved in pathophysiological conditions, such as atherosclerosis, inflammation, and fibrosis. Direct inhibition of FXa by DOACs could be beneficial in these conditions. This is a narrative review that focuses on the cellular effects of FXa in various cell types and conditions, as well as on the possible pleiotropic effects of FXa-targeting DOACs.
- Published
- 2019
- Full Text
- View/download PDF
12. Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats.
- Author
-
Mahmoud NI, Messiha BAS, Salehc IG, Abo-Saif AA, and Abdel-Bakky MS
- Subjects
- Animals, Anticoagulants metabolism, Anticoagulants pharmacology, Biomarkers metabolism, Blood Platelets drug effects, Blood Platelets metabolism, Carbon Tetrachloride pharmacology, Clopidogrel metabolism, Dabigatran metabolism, Liver metabolism, Liver Cirrhosis metabolism, Liver Cirrhosis physiopathology, Male, Oxidative Stress drug effects, Rats, Thrombin drug effects, Thrombin metabolism, Clopidogrel pharmacology, Dabigatran pharmacology, Liver Cirrhosis drug therapy
- Abstract
Aim: Liver fibrosis is a serious health problem which is a critical cause of morbidity and mortality worldwide. It is the main complication of untreated chronic inflammatory liver diseases which can progress to liver cirrhosis, hepatocellular carcinoma, and finally death. Coagulation cascade plays a mechanistic role in the pathogenesis of different chronic inflammatory disease including atherosclerosis, stroke, and tissue fibrosis. The current study was designed to investigate the effect of inhibition of coagulation cascade on carbon tetrachloride (CCl
4 )-induced liver fibrosis in rats., Material and Methods: The study was conducted in rats. Rats were treated with CCl4 subcutaneously for 6 consecutive weeks to determine the onset of coagulation system activation in relation to development of fibrosis. To investigate the effects of coagulation system inhibition in CCl4 -induced liver fibrosis, the anticoagulants drugs dabigatran and clopidogrel were administrated orally concurrently with CCl4 treatment., Key Findings: The results of our study revealed that during the first week, there were significant elevations of fibrin, tissue factor expressions, and prothrombin time (PT) coupled with neutropenia without significant changes in liver fibrosis markers such as TGF-β, α-SMA and collagen deposition. Starting from the second week, tissue injury markers including the oxidative, inflammatory and fibrosis markers as well as histopathological changes became evident progressively. Intriguingly, dabigatran and clopidogrel significantly normalized the biochemical and pathological changes., Significance: In conclusion, activation of coagulation cascade is a triggering stimulus in the initiation of CCl4 -induced liver fibrosis and the anticoagulant drugs may exert promising anti-fibrotic effect., (Copyright © 2019 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
13. Contradictory to its effects on thrombin, C1-inhibitor reduces plasmin generation in the presence of thrombomodulin.
- Author
-
Tarandovskiy ID, Rajabi AA, Karnaukhova E, and Buehler PW
- Subjects
- Blood Coagulation, Blood Specimen Collection, Dose-Response Relationship, Drug, Fibrinolysin biosynthesis, Fibrinolysis drug effects, Healthy Volunteers, Humans, Thrombin metabolism, Thrombosis chemically induced, Complement C1 Inhibitor Protein pharmacology, Fibrinolysin antagonists & inhibitors, Thrombin drug effects, Thrombomodulin physiology
- Abstract
C1-inhibitor (C1INH) was shown to enhance thrombin generation (TG) in the presence of thrombomodulin (TM) by reducing production of activated protein C. Because C1INH is known to inhibit fibrinolytic system proteases, the objective of this study was to evaluate the effect of moderate (3 IU/ml) and high (16 IU/ml) C1INH concentrations on TG and plasmin generation (PG) in the presence of TM. These concentrations were evaluated based on expected maximum plasma levels following C1INH replacement therapy and recently suggested supraphysiologic dosing. TG and PG were investigated in platelet poor plasmas obtained from 21 healthy donors. An assay designed to monitor the continuous generation of the 7-amino-4-methylcoumarin fluorescence from substrates specific to thrombin or plasmin was used to evaluate the impact of C1INH activity. To characterize the C1INH effects on TG and PG, the thrombin and plasmin concentration peaks and production rates were calculated. TM addition to donor plasma shifted the concentration dependence of C1INH on TG parameters from reduction to enhancement. Conversely, PG parameters were significantly reduced by 16 IU/ml in both the presence and absence of TM. Moderate C1INH concentration (3 IU/ml) reduced TG and PG in the absence of TM but did not significantly affect these parameters in the presence of TM. Finally, 3 IU/ml of C1INH reduced PG more so than TG in the absence of TM. The presented results suggest a mechanism by which C1INH could potentiate thrombosis by inhibition of fibrinolysis.
- Published
- 2019
- Full Text
- View/download PDF
14. The effect of hirudin on antagonisting thrombin induced apoptosis of human microvascular endothelial cells1.
- Author
-
Zhu J, Pan X, Lin B, Lin G, Pradhan R, Long F, and Yin G
- Subjects
- Cell Proliferation drug effects, Humans, Microvessels drug effects, Microvessels metabolism, Signal Transduction drug effects, Antithrombins pharmacology, Apoptosis drug effects, Endothelial Cells drug effects, Hirudins pharmacology, Protein Kinase Inhibitors pharmacology, Thrombin drug effects
- Abstract
Purpose: To investigate whether hirudin exerts its antithrombin action to decrease the ratio of Human Microvascular Endothelial Cells (HMVECs) apoptosis., Methods: Human microvascular endothelial cells (HMVECs) cultured in the third and fifth generations were used. HMVECs were divided into normal group, thrombin group (T group), natrual hirudin group (H group), thrombin + natrual hirudin group (T + H group), AG490 group, thrombin + AG490 group (T + AG490 group), natrual hirudin + AG490 group (H + AG490 group), thrombin + natural hirudin + AG490 (T + H + AG490 group).Apart from the normal group, the other groups were exposed to the relevant drugs for 24 hours.HMVEC apoptosis was assessed by flow cytometric and double Immunofluorescence of phosphorylation of JAK (P-JAK2) and TUNEL assay., Results: Compared with the normal group, in thrombin group the HMVECs apoptosis rate were significantly increased (P<0.05).The results indicated that the index of apoptosis and the apoptosis rate were improved in cultures treated by natural hirudin (T + H group), relative to cultures with thrombin only (T group). We found that the index of apoptosis and the apoptosis rate in the AG490 + thrombin group were higher than that in the hirudin + thrombin group (P<0.05). Double Immunofluorescence of p-JAK2 and TUNEL assays showed that cells were double positive for P-JAK2 uptake and TUNEL detection liquid binding., Conclusion: The natural hirudin and JAK2/STATs signal inhibitor AG490 could block the effects of thrombin. Natural hirudin could attenuate HMVECs apoptosis via antagonizing thrombin and it is suggested that this effect may occur by blocking the JAK2/STATs signaling pathway and this signaling pathways appears to be not the only pathway.
- Published
- 2019
- Full Text
- View/download PDF
15. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
- Author
-
Siddiqui F, Tafur A, Ramacciotti LS, Jeske W, Hoppensteadt D, Ramacciotti E, Iqbal O, and Fareed J
- Subjects
- Anticoagulants pharmacology, Benzamides pharmacology, Blood Coagulation Tests, Factor Xa Inhibitors chemistry, Humans, Pyrazoles pharmacology, Pyridines pharmacology, Pyridones pharmacology, Rivaroxaban pharmacology, Thiazoles pharmacology, Thrombin drug effects, Drug Antagonism, Factor Xa pharmacology, Factor Xa Inhibitors pharmacology, Recombinant Proteins pharmacology, Thrombin biosynthesis
- Abstract
Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors. We studied the reversal effect of AA for these inhibitors in various anticoagulant and thrombin generation (TG) assays. Individual aliquots of normal human plasma containing 1 µg/mL of apixaban, betrixaban, edoxaban, and rivaroxaban, were supplemented with saline or AA at a concentration of 100 µg/mL. Clotting profiles include prothrombinase-induced clotting time, activated partial thromboplastin time, and prothrombin time. Factor Xa activity was measured using an amidolytic method. Thrombin generation was measured using a calibrated automated thrombogram. Differential neutralization of all 4 anticoagulants was noted in the activated clotting time and other clotting tests. The FXa activity reversal profile varied with an observed decrease in apixaban (22%), betrixaban (56%), edoxaban (28%), and rivaroxaban (49%). Andexanet alfa also led to an increased TG in comparison to saline. The peak thrombin was higher (40%), area under the curve (AUC) increased (15%), whereas the lag time (LT) decreased (17%). Andexanet alfa added at 100 µg/mL to various FXa supplemented systems resulted in reversal of the inhibitory effects, restoring the TG profile; AUC, LT, and peak thrombin levels were comparable to those of unsupplemented samples. Andexanet alfa is capable of reversing anti-Xa activity of different oral FXa inhibitors but overshoots thrombogenesis in both the saline and FXa inhibitor supplemented systems. The degree of neutralization of Xa inhibitor is specific to each agent.
- Published
- 2019
- Full Text
- View/download PDF
16. Food-derived antithrombotic peptides: Preparation, identification, and interactions with thrombin.
- Author
-
Cheng S, Tu M, Liu H, Zhao G, and Du M
- Subjects
- Animals, Anticoagulants pharmacology, Food, Humans, Peptides isolation & purification, Thrombosis, Fibrinolytic Agents isolation & purification, Fibrinolytic Agents pharmacology, Peptides pharmacology, Thrombin drug effects
- Abstract
Thromboembolism and its sequelae have been the leading causes of morbidity and mortality throughout the world. Food-derived antithrombotic peptides, as potential ingredients in health-promoting functional foods targeting thrombus, have attracted increasing attention because of their high biological activities, low toxicity, and ease of metabolism in the human body. This review presents the conventional workflow of preparation, isolation and identification of antithrombotic peptides from various kinds of food materials. More importantly, to analyze the antithrombotic effects and mechanism of antithrombotic peptides, methods for interaction of anticoagulant peptides and thrombin, the main participant in thrombosis, were analyzed from biochemistry, solution chemistry and crystal chemistry. The present study is intended to highlight the recent advances in research of food-derived antithrombotic peptide as a novel vehicle in the field of food science and nutrition. Future outlooks are highlighted with the aim to suggest a research line to be followed in further studies with the introduced research approach.
- Published
- 2019
- Full Text
- View/download PDF
17. Thrombin Generation in Chinese Pregnant Women and the Effect of Insulin Use on Thrombin Generation in Patients with GDM.
- Author
-
Dong F, Wang L, and Wang C
- Subjects
- Adult, Blood Glucose, Diabetes, Gestational blood, Female, Humans, Insulins therapeutic use, Pregnancy, Pregnancy Complications, Pregnancy Trimesters, Reference Values, Risk Assessment, Thrombin drug effects, Thrombin standards, Thrombosis chemically induced, Thrombosis etiology, Diabetes, Gestational drug therapy, Insulins pharmacology, Thrombin biosynthesis
- Abstract
Pregnancy is a hypercoagulable state associated with an increased risk of venous thrombosis. Calibrated automated thrombogram (CAT) is a test to monitor the thrombin generation (TG), a laboratory marker of thrombosis risk, and increases during normal pregnancy, but it is still unclear whether TG is related to the use of insulin in pregnant women with gestational diabetes mellitus (GDM). We performed thrombin generation by CAT on 135 normal pregnant women, including 43 in first trimester, 32 in second trimester, 60 in third trimester, respectively; 68 pregnant women with GDM were also enrolled, 19 patients with GDM using insulin to control blood glucose and 49 patients control their blood glucose through diet and exercise with noninsulin treatment. The overall CAT parameters were calculated using descriptive statistics method with mean ± standard deviation. Mean endogenous thrombin potential, peak thrombin generation, and StartTail time increased significantly with the pregnancy. There was no significant difference in TG test parameters except StartTail time( P = .003) in insulin-treated GDM group when compared to those without insulin in the GDM group. The normal ranges for CAT parameters in pregnant women were determined. Thrombin generation increased significantly in first trimester and remains stable in second and third trimester. The use of insulin in patient with GDM did not affect thrombin generation test. Our study helps to establish the reference range of thrombin generation in Chinese normal pregnant population and provide more basis to predict the risk of thrombus complicating during pregnancy.
- Published
- 2019
- Full Text
- View/download PDF
18. Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study.
- Author
-
Barg AA, Levy-Mendelovich S, Avishai E, Dardik R, Misgav M, Kenet G, and Livnat T
- Subjects
- Adolescent, Blood Coagulation Tests methods, Child, Preschool, Humans, Male, Recombinant Proteins therapeutic use, Thrombin drug effects, Blood Coagulation Factors therapeutic use, Factor VIIa therapeutic use, Hemophilia B drug therapy, Thrombin biosynthesis
- Abstract
Little is known about the challenging treatment of pediatric patients with hemophilia B and inhibitors due to disease rarity. We describe three patients diagnosed in childhood and followed up to 9 years. All three had allergic reactions to Factor IX, but two were later safely treated for bleeding episodes with activated prothrombin complex concentrates (APCC = FEIBA). The third was given only recombinant activated Factor VIIa. Based on ex vivo thrombin generation analysis, a new alternative treatment of combined bypassing agents was administered for bleeding episodes and several minor surgical procedures with no treatment-associated adverse events or thrombosis., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
19. A pilot study documenting increased thrombin generation following abrupt withdrawal of heparin therapy in healthy dogs.
- Author
-
Mays EM, Dorman DC, McKendry C, and Hanel RM
- Subjects
- Animals, Anticoagulants administration & dosage, Dogs, Heparin administration & dosage, Infusions, Intravenous veterinary, Male, Pilot Projects, Prospective Studies, Thrombelastography veterinary, Thrombin biosynthesis, Anticoagulants pharmacology, Heparin pharmacology, Thrombin drug effects
- Abstract
Objective: To document if a transient hypercoagulable state occurs in healthy dogs following abrupt cessation of unfractionated heparin (UFH) therapy., Design: Prospective experimental pilot study., Setting: University research facility., Animals: Seven adult random-source male dogs., Intervention: Thromboelastography (TEG) and thrombin-antithrombin (TAT) complex formation were used to assess coagulation status in healthy dogs. Seven adult research dogs received 200-300 IU/kg subcutaneous UFH every 8 hours for 4 days. A final IV bolus of 100 IU/kg was given on day 4 and the peak measured heparin concentration 1 hour later is defined as the start of heparin withdrawal (time 0). Citrated whole blood samples were collected at baseline (prior to heparin administration) and 3, 6, 12, 30, and 48 hours after UFH withdrawal. At all time points, a kaolin-activated TEG was performed and citrated plasma for measurement of TAT concentration was collected for batch analysis. Fibrinogen concentration, PCV, total plasma proteins, and platelet count were measured at baseline and 48 hours after heparin withdrawal., Measurements and Main Results: Compared to baseline, TAT was increased 12 hours after heparin withdrawal and returned to baseline by 30 hours. TEG clot formation time (K) was decreased 30 and 48 hours after heparin withdrawal., Conclusion: TAT results suggest that a transient increase in thrombin generation developed 12 hours after withdrawal of UFH therapy. Though clot kinetics were rapid compared to baseline beginning 30 hours after heparin withdrawal, a return to baseline was not documented. Future studies are warranted to determine the clinical relevance of these results and to evaluate the effect of UFH withdrawal in critically ill animals., (© Veterinary Emergency and Critical Care Society 2018.)
- Published
- 2018
- Full Text
- View/download PDF
20. Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay.
- Author
-
Kopatz WF, Brinkman HJM, and Meijers JCM
- Subjects
- Administration, Oral, Anticoagulants pharmacology, Blood Coagulation drug effects, Humans, Thrombin pharmacology, Anticoagulants therapeutic use, Thrombin drug effects
- Abstract
Calibrated automated thrombography (CAT) is useful in monitoring the anticoagulant status of patients treated with direct oral anticoagulants (DOACs). This as well as other applications of the CAT are hampered by the wide inter-individual variation, making the diagnosis of the anticoagulant status of a patient on DOAC difficult when using normal pooled plasma as a reference. With dabigatran, the CAT is further hampered, as this direct thrombin inhibitor also inhibits the calibrator that is used in CAT. In this study we examined the added value of the universal DOAC adsorbent DOAC Stop in CAT. For this, we used normal pooled plasma spiked with apixaban, dabigatran, edoxaban or rivaroxaban, and performed CAT with 5 pM tissue factor. DOAC Stop effectively removed DOACs from plasma, leaving the DOAC Stop-treated plasma slightly more procoagulant compared to sham treated, non-anticoagulated plasma. Examining levels of natural coagulation inhibitors revealed a slight reduction in tissue factor pathway inhibitor upon DOAC Stop treatment. When DOAC Stop-treated plasma was used in the calibrator wells, normal unaffected calibration curves were observed, even when dabigatran was present. In conclusion, DOAC Stop can be used to abolish dabigatran influences of anticoagulated plasma when used in the calibrator wells. Also, the anticoagulant status of a DOAC treated patient can be diagnosed simply by comparing untreated plasma with the same plasma sample treated with DOAC Stop. Using this approach, a minor DOAC-independent increase in CAT response in the DOAC Stop-treated sample should be taken into account., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
21. Production of platelet-rich plasma gel from elderly patients under antithrombotic drugs: Perspectives in chronic wounds care.
- Author
-
Velier M, Magalon J, Daumas A, Cassar M, Francois P, Ghazouane A, Philandrianos C, Bertrand B, Frere C, Bernot D, Villani P, George FD, and Sabatier F
- Subjects
- Adult, Chronic Disease, Female, Fibrinolytic Agents pharmacology, Humans, Male, Middle Aged, Fibrinolytic Agents therapeutic use, Platelet-Rich Plasma metabolism, Thrombin drug effects, Wound Healing drug effects
- Abstract
Platelet-Rich Plasma (PRP) is an autologous biological therapy obtained by centrifuging the patient's own blood to concentrate platelets. The addition of autologous thrombin and calcium chloride to PRP allows the production of a semi-solid form called PRP gel. PRP gel is increasingly used in a variety of tissue defects and predominantly in the management of non-healing chronic wounds. The topical application of PRP gel seems promising due to the capability of platelets to store and secrete growth factors (GF), fibrin and cytokines, which are essentials for wound healing. Most patients who suffered from chronic wounds are elderly patients with co-morbidities and polypharmacy including antithrombotic drugs such as antiplatelet agents (AP) or anticoagulants (AC), which could hamper the feasibility of this autologous platelet-derived therapy. To date, no study has investigated PRP gel formation in patients with AP or AC. The aim of this study was to evaluate the influence of AP or AC drugs on the production of PRP gel formation from elderly patients. Different biological characteristics were determined to qualify the production of PRP gel from such patients (Interquartile range (IQR) = 75-92 years) compared to healthy volunteers (IQR = 23-37 years). No significant difference was observed in the volume, composition (quantity of platelets, leukocytes and red blood cells) and functionality of platelets from PRP except a higher ADP-induced P-selectin expression in healthy donors compared with elderly patients. Autologous thrombin characteristics were similar in the two groups. Gel time formation (IQR: 120-195 seconds for controls and 135-210 seconds for elderly patients) and final composition of PRP gel were not significantly modified. Concentrations of theoretical thrombin generated in the serum and in the gel were inversely correlated with the time of formation of PRP gel (r
2 = 0.57, p = 0.012). Altogether these data indicate that PRP gel preparation is not impacted by the use of antithrombotic drugs. Such results support the feasibility of using this innovative autologous biotherapy in the management of elderly patients with non-healing chronic wounds.- Published
- 2018
- Full Text
- View/download PDF
22. The effect of dabigatran on thrombin generation and coagulation assays in rabbit and human plasma.
- Author
-
Zhang C, Zhang P, Li H, Han L, Zhang L, Zhang L, and Yang X
- Subjects
- Animals, Antithrombins pharmacology, Dabigatran pharmacology, Female, Humans, Male, Rabbits, Antithrombins therapeutic use, Blood Coagulation drug effects, Blood Coagulation Tests methods, Dabigatran therapeutic use, Thrombin drug effects
- Abstract
Objectives: Dabigatran etexilate is widely used for stroke prevention in the patients with atrial fibrillation. The anticoagulation activity of dabigatran is not necessary monitored in routine clinical practice. We aimed to study the effect of dabigatran on thrombin generation (TG) and coagulation assays in rabbit and human plasma., Methods: Rabbits received different concentrations of dabigatran etexilate (5 mg/kg, 10 mg/kg). Patients with atrial fibrillation took 110 mg dabigatran etexilate twice daily. The concentrations of dabigatran in rabbit and human plasma were detected by liquid chromatography/tandem mass spectrometry (LC-MS/MS) and ecarin chromogenic assay (ECA). The relationship between plasma dabigatran concentrations and the activated partial thromboplastin time (aPTT), prothrombin time (PT), thrombin time (TT), and TG were evaluated., Results: There was strong correlation between LC-MS/MS and ECA (P < 0.001). Bland Altman analysis demonstrated that ECA assay could accurately predict human plasma dabigatran concentrations whereas underestimate the plasma concentrations of dabigatran in rabbits. Both the PT and the aPTT assays showed low correlations with dabigatran. The TT assay was highly sensitive to dabigatran levels. Low concentrations of dabigatran paradoxically increased TG., Conclusions: LC-MS/MS is the gold standard for detecting the concentrations of dabigatran. ECA correlates well with LC-MS/MS. The coagulation assays depend more on other factors. Paradoxical enhancement of TG may predict clinically rebound hypercoagulability and warrants further exploration., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
23. Low dose of alcohol attenuates pro-atherosclerotic activity of thrombin.
- Author
-
Toda M, Totoki T, Nakamura C, Yasuma T, D' Alessandro-Gabazza CN, Mifuji-Moroka R, Nishihama K, Iwasa M, Horiki N, Gabazza EC, and Takei Y
- Subjects
- Animals, Atherosclerosis prevention & control, Blood Coagulation drug effects, Cells, Cultured, Dose-Response Relationship, Drug, Ethanol pharmacology, Ethanol therapeutic use, Humans, Inflammation prevention & control, Mice, Atherosclerosis etiology, Ethanol administration & dosage, Thrombin drug effects, Thrombin physiology
- Abstract
Background and Aims: Thrombin, the active enzyme of the coagulation system, plays a critical role in the pathogenesis of atherosclerosis. Vascular repair promoted by stromal cell-derived factor-1 is a protective process in atherosclerosis. Consumption of low amount of alcohol is believed to reduce the risk of atherosclerotic cardiovascular disease but the mechanism is unclear. This study evaluated whether alcohol can modulate the expression of stromal cell-derived factor-1 and the pro-atherosclerotic activity of thrombin., Methods: Hepatocytes, monocytes, vascular endothelial and vascular smooth muscle cells were pre-treated with increasing concentrations of ethanol before stimulation with thrombin. The expression of cytokines, chemokines, cell adhesion molecules and epigenetic factors, including histone deacetylases and sirtuins, was evaluated., Results: Thrombin stimulation significantly enhanced the expression of pro-inflammatory cytokines, chemokines and cell adhesion molecules, but significantly decreased the expression of stromal cell-derived factor-1. Pre-treatment of cells with a low dose of ethanol significantly decreased thrombin-induced production of pro-inflammatory cytokines and chemokines, and significantly increased the production of stromal cell-derived factor-1 compared to cells treated with thrombin alone. Ethanol significantly counteracted the decreased expression of histone deacetylases and sirtuins induced by thrombin. Inhibition of histone deacetylase-2 with trichostatin A or with specific siRNA abolished the stimulatory activity of low-dose ethanol on stromal cell-derived factor-1., Conclusions: Low-dose of ethanol attenuates the inflammatory response and counteracts the reduced expression of stromal cell-derived factor-1 induced by thrombin via an epigenetic mechanism, providing a potential explanation for the protective activity of low dose of alcohol in atherosclerosis., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
24. FVIIa-sTF and Thrombin Inhibitory Activities of Compounds Isolated from Microcystis aeruginosa K-139.
- Author
-
Anas ARJ, Mori A, Tone M, Naruse C, Nakajima A, Asukabe H, Takaya Y, Imanishi SY, Nishizawa T, Shirai M, and Harada KI
- Subjects
- Blood Coagulation, Cyanobacteria, Depsipeptides, Factor VIIa, Humans, Japan, Leupeptins, Models, Molecular, Thromboplastin, Anticoagulants pharmacology, Microcystis chemistry, Thrombin drug effects
- Abstract
The rise of bleeding and bleeding complications caused by oral anticoagulant use are serious problems nowadays. Strategies that block the initiation step in blood coagulation involving activated factor VII-tissue factor (fVIIa-TF) have been considered. This study explores toxic Microcystis aeruginosa K-139, from Lake Kasumigaura, Ibaraki, Japan, as a promising cyanobacterium for isolation of fVIIa-sTF inhibitors. M. aeruginosa K-139 underwent reversed-phase solid-phase extraction (ODS-SPE) from 20% MeOH to MeOH elution with 40%-MeOH increments, which afforded aeruginosin K-139 in the 60% MeOH fraction; micropeptin K-139 and microviridin B in the MeOH fraction. Aeruginosin K-139 displayed an fVIIa-sTF inhibitory activity of ~166 µM, within a 95% confidence interval. Micropeptin K-139 inhibited fVIIa-sTF with EC
50 10.62 µM, which was more efficient than thrombin inhibition of EC50 26.94 µM. The thrombin/fVIIa-sTF ratio of 2.54 in micropeptin K-139 is higher than those in 4-amidinophenylmethane sulfonyl fluoride (APMSF) and leupeptin, when used as positive controls. This study proves that M. aeruginosa K-139 is a new source of fVIIa-sTF inhibitors. It also opens a new avenue for micropeptin K-139 and related depsipeptides as fVIIa-sTF inhibitors., Competing Interests: The authors declare no conflict of interest.- Published
- 2017
- Full Text
- View/download PDF
25. Thrombin impairs human endometrial endothelial angiogenesis; implications for progestin-only contraceptive-induced abnormal uterine bleeding.
- Author
-
Shapiro JP, Guzeloglu-Kayisli O, Kayisli UA, Semerci N, Huang SJ, Arlier S, Larsen K, Fadda P, Schatz F, and Lockwood CJ
- Subjects
- Cells, Cultured, Chondroitin Sulfate Proteoglycans analysis, Chondroitin Sulfate Proteoglycans metabolism, Chondroitin Sulfate Proteoglycans pharmacology, Endothelium blood supply, Endothelium drug effects, Female, Humans, Membrane Proteins analysis, Membrane Proteins metabolism, Membrane Proteins pharmacology, Neovascularization, Pathologic physiopathology, Recombinant Proteins pharmacology, Stromal Cells chemistry, Thrombin drug effects, Thrombin physiology, Contraceptive Agents, Female adverse effects, Endometrium blood supply, Neovascularization, Pathologic chemically induced, Progestins adverse effects, Thrombin pharmacology, Uterine Hemorrhage chemically induced
- Abstract
Objective: Progestin-only contraceptives induce abnormal uterine bleeding, accompanied by prothrombin leakage from dilated endometrial microvessels and increased thrombin generation by human endometrial stromal cell (HESC)-expressed tissue factor. Initial studies of the thrombin-treated HESC secretome identified elevated levels of cleaved chondroitin sulfate proteoglycan 4 (CSPG4), impairing pericyte-endothelial interactions. Thus, we investigated direct and CSPG4-mediated effects of thrombin in eliciting abnormal uterine bleeding by disrupting endometrial angiogenesis., Study Design: Liquid chromatography/tandem mass spectrometry, enzyme-linked immunosorbent assay (ELISA) and quantitative real-time-polymerase chain reaction (PCR) evaluated conditioned medium supernatant and cell lysates from control versus thrombin-treated HESCs. Pre- and post-Depo medroxyprogesterone acetate (DMPA)-administered endometria were immunostained for CSPG4. Proliferation, apoptosis and tube formation were assessed in human endometrial endothelial cells (HEECs) incubated with recombinant human (rh)-CSPG4 or thrombin or both., Results: Thrombin induced CSPG4 protein expression in cultured HESCs as detected by mass spectrometry and ELISA (p<.02, n=3). Compared to pre-DMPA endometria (n=5), stromal cells in post-DMPA endometria (n=5) displayed stronger CSPG4 immunostaining. In HEEC cultures (n=3), total tube-formed mesh area was significantly higher in rh-CSPG4 versus control (p<.05). However, thrombin disrupted HEEC tube formation by a concentration- and time-dependent reduction of angiogenic parameters (p<.05), whereas CSPG4 co-treatment did not reverse these thrombin-mediated effects., Conclusion: These results suggest that disruption of HEEC tube formation by thrombin induces aberrant angiogenesis and abnormal uterine bleeding in DMPA users., Implications: Mass spectrometry analysis identified several HESC-secreted proteins regulated by thrombin. Therapeutic agents blocking angiogenic effects of thrombin in HESCs can prevent or minimize progestin-only contraceptive-induced abnormal uterine bleeding., (Copyright © 2017. Published by Elsevier Inc.)
- Published
- 2017
- Full Text
- View/download PDF
26. Effects of thromboprophylactic doses of apixaban and rivaroxaban on coagulation and thrombin generation in association with total hip replacement.
- Author
-
Helin TA, Virtanen L, Manninen M, Leskinen J, Leppilahti J, Joutsi-Korhonen L, and Lassila R
- Subjects
- Blood Coagulation Tests instrumentation, Blood Coagulation Tests methods, Drug Combinations, Factor Xa Inhibitors therapeutic use, Female, Humans, Male, Thrombin drug effects, Time Factors, Arthroplasty, Replacement, Hip methods, Blood Coagulation drug effects, Premedication methods, Pyrazoles administration & dosage, Pyridones administration & dosage, Rivaroxaban administration & dosage, Thrombin biosynthesis
- Abstract
Factor Xa inhibitors (FXaI) apixaban and rivaroxaban are used for thromboprophylaxis after major elective orthopaedic surgery. Because few patient sample studies exist, we postoperatively assessed patients undergoing unilateral total hip arthroplasty, including 22 treated with apixaban (2.5 mg BID) and 20 treated with rivaroxaban (10 mg OD). We collected blood samples before and 3 h after drug intake at 4 time points, preoperatively, as well as on day 1, week 1 (day 2-8) and day 28 post-operation. APTT and PT were immediately analysed. Calibrated anti-FXa activity, Russel's Viper Venom Time (RVVT) and thrombin generation (TG; Calibrated Automated Thrombogram
® ) captured the effects of FXaI on coagulation and TG. APTT and PT remained within the reference interval throughout, and did not correlate with FXaI levels (PT R2 = 0.44, APTT R2 = 0.07). Mean apixaban concentration at the peak varied by eightfold (19-153 ng/mL), but rivaroxaban only by 1.5-fold (111-183 ng/mL). Rivaroxaban, but not apixaban prolonged RVVT at peak levels. Both FXaIs had a prolonged lag time of TG (p < 0.001). Rivaroxaban decreased ETP peak at all time points and reached a minimum at day 28 (540 nM/min at rivaroxaban 184 ng/mL, p < 0.001), while rivaroxaban trough levels were low and ETP values normal. However, with apixaban, after an initial decrease, ETP did not differ between peak and trough levels until decreasing on day 28 at peak (990 nM/min at apixaban 112 ng/mL, p = 0.005). In conclusion, due to different dosing and pharmacology rivaroxaban and apixaban distinctly inhibited TG under postoperative conditions.- Published
- 2017
- Full Text
- View/download PDF
27. Unlike tocilizumab, etanercept slightly increases experimental thrombin-induced aggregation in healthy individuals.
- Author
-
Cognasse F, Garraud O, and Marotte H
- Subjects
- Enzyme-Linked Immunosorbent Assay, Healthy Volunteers, Humans, In Vitro Techniques, Platelet-Rich Plasma, Sensitivity and Specificity, Antibodies, Monoclonal, Humanized pharmacology, Etanercept pharmacology, Platelet Aggregation drug effects, Thrombin drug effects
- Published
- 2017
- Full Text
- View/download PDF
28. The Antithrombotic Potential of Tinzaparin and Enoxaparin Upon Thrombin Generation Triggered In Vitro by Human Ovarian Cancer Cells IGROV1.
- Author
-
Sassi M, Chakroun T, Mbemba E, Van Dreden P, Elalamy I, Larsen AK, and Gerotziafas GT
- Subjects
- Cell Line, Tumor, Dose-Response Relationship, Drug, Enoxaparin pharmacology, Factor Xa Inhibitors blood, Female, Humans, Ovarian Neoplasms drug therapy, Ovarian Neoplasms metabolism, Plasma, Prothrombin antagonists & inhibitors, Thrombin drug effects, Thromboplastin analysis, Thromboplastin drug effects, Tinzaparin, Fibrinolytic Agents pharmacology, Heparin, Low-Molecular-Weight pharmacology, Ovarian Neoplasms pathology, Thrombin biosynthesis
- Abstract
Background: A documented relationship between ovarian cancer and thrombosis does exist. Low-molecular-weight heparins (LMWHs) are cornerstone drugs in the primary prevention and treatment of venous thromboembolic events in patients with cancer. However, cancer cells may alter the efficiency of these antithrombotic agents., Objective: We aimed to characterize the procoagulant phenotype of human epithelial ovarian adenocarcinoma cells, IGROV1, and to compare the capacity of tinzaparin and enoxaparin to inhibit thrombin generation triggered by these cells., Methods: Thrombin generation induced by different concentrations of IGROV1 cells on platelet poor plasma (PPP) was assessed by the calibrated automated thrombogram assay. Tissue factor (TF) expression was studied using Western blot analysis. Then, the experimental model of thrombin generation was used to compare the inhibitory effect of clinically relevant concentrations of both tinzaparin and enoxaparin. The inhibitory concentration 50 (IC50) of the mean rate index and the endogenous thrombin potential and the 2-fold increase in lag time were analyzed on the basis of the anti-Xa and anti-IIa activities of the LMWHs., Results: IGROV1 cells suspended into PPP resulted in a significant increase in thrombin generation in the absence of any exogenous source of TF and phospholipids. Tissue factor was expressed by IGROV1 cells. Tinzaparin was a more potent inhibitor of thrombin generation than enoxaparin. The inhibition of thrombin generation induced by IGROV1 cancer cells depended mainly on the anti-Xa activity of the LMWHs., Conclusion: This experimental study in ovarian cancer cells demonstrates that the antithrombotic activity of LMWHs is not completely predicted by the anti-Xa or anti-IIa activities measured in PPP.
- Published
- 2017
- Full Text
- View/download PDF
29. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation.
- Author
-
Stopa JD, Neuberg D, Puligandla M, Furie B, Flaumenhaft R, and Zwicker JI
- Subjects
- Administration, Oral, Animals, Antiphospholipid Syndrome immunology, Humans, Models, Animal, Quercetin administration & dosage, Quercetin pharmacology, Blood Coagulation Factors drug effects, Protein Disulfide-Isomerases drug effects, Quercetin analogs & derivatives, Thrombin drug effects
- Abstract
BACKGROUND : Protein disulfide isomerase (PDI) is required for thrombus formation. We previously demonstrated that glycosylated quercetin flavonoids such as isoquercetin inhibit PDI activity and thrombus formation in animal models, but whether extracellular PDI represents a viable anticoagulant target in humans and how its inhibition affects blood coagulation remain unknown. METHODS : We evaluated effects of oral administration of isoquercetin on platelet-dependent thrombin generation in healthy subjects and patients with persistently elevated anti-phospholipid antibodies. RESULTS : Following oral administration of 1,000 mg isoquercetin to healthy adults, the measured peak plasma quercetin concentration (9.2 μM) exceeded its IC
50 for inhibition of PDI by isoquercetin in vitro (2.5 ± 0.4 μM). Platelet-dependent thrombin generation decreased by 51% in the healthy volunteers compared with baseline ( P = 0.0004) and by 64% in the anti-phospholipid antibody cohort ( P = 0.015) following isoquercetin ingestion. To understand how PDI affects thrombin generation, we evaluated substrates of PDI identified using an unbiased mechanistic-based substrate trapping approach. These studies identified platelet factor V as a PDI substrate. Isoquercetin blocked both platelet factor Va and thrombin generation with an IC50 of ~5 μM. Inhibition of PDI by isoquercetin ingestion resulted in a 53% decrease in the generation of platelet factor Va ( P = 0.001). Isoquercetin-mediated inhibition was reversed with addition of exogenous factor Va. CONCLUSION : These studies show that oral administration of isoquercetin inhibits PDI activity in plasma and diminishes platelet-dependent thrombin generation predominantly by blocking the generation of platelet factor Va. These pharmacodynamic and mechanistic observations represent an important step in the development of a novel class of antithrombotic agents targeting PDI. TRIAL REGISTRATION : Clinicaltrials.gov (NCT01722669) FUNDING : National Heart, Lung, and Blood Institute (U54 HL112302) and Quercegen Pharma., Competing Interests: J.I. Zwicker received research support from Quercegen Pharma.- Published
- 2017
- Full Text
- View/download PDF
30. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
- Author
-
Schenk B, Würtinger P, Streif W, Sturm W, Fries D, and Bachler M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants pharmacology, Blood Coagulation Tests methods, Female, Humans, Male, Middle Aged, Thrombin metabolism, Young Adult, Blood Coagulation drug effects, Factor Xa Inhibitors pharmacology, Rivaroxaban pharmacology, Thrombelastography methods, Thrombin drug effects
- Abstract
Background: In major bleeding events, the new direct oral anticoagulants pose a great challenge for physicians. The aim of the study was to test for ex vivo reversal of the direct oral anticoagulant rivaroxaban with various non-specific reversal agents: prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (aPCC), recombinant activated factor VII (rFVIIa), and fibrinogen concentrate (FI)., Methods: Blood was obtained from healthy volunteers and from patients treated with rivaroxaban. Blood samples from healthy volunteers were spiked with rivaroxaban to test the correlation between rivaroxaban concentration and coagulation tests. Patient blood samples were spiked with various concentrations of the above-mentioned agents and analysed using thromboelastometry and thrombin generation., Results: When added in vitro, rivaroxaban was significantly (P<0.05) correlated with ROTEM
® thromboelastometry EXTEM (extrinsic coagulation pathway) clotting time (CT), time to maximal velocity (MaxV-t), and with all measured thrombin generation parameters. In vivo, CT, MaxV-t, lag time, and peak thrombin generation (Cmax ) were significantly correlated with rivaroxaban concentrations. Regarding reversal of rivaroxaban, all tested agents significantly (P<0.05) reduced EXTEM CT, but to different extents: rFVIIa by 68%, aPCC by 47%, PCC by 17%, and FI by 9%. Only rFVIIa reversed EXTEM CT to baseline values. Both PCC (+102%) and aPCC (+232%) altered overall thrombin generation (area under the curve) and increased Cmax (+461% for PCC, +87.5% for aPCC)., Conclusions: Thromboelastometry and thrombin generation assays do not favour the same reversal agents for rivaroxaban anticoagulation. Controlled clinical trials are urgently needed to establish doses and clinical efficacy of potential reversal agents., Clinical Trial Registration: EudracCT trial no. 213-00474-30., (© The Author 2016. Published by Oxford University Press on behalf of the British Journal of Anaesthesia.)- Published
- 2016
- Full Text
- View/download PDF
31. [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
- Author
-
Neira V, Corbalán R, Pereira J, Panes O, Garayar B, Aizman A, Llevaneras S, and Villarroel L
- Subjects
- Administration, Oral, Aged, Aged, 80 and over, Factor Xa metabolism, Female, Humans, Male, Prospective Studies, Prothrombin Time, Thrombin metabolism, Time Factors, Antithrombin III drug effects, Atrial Fibrillation blood, Factor Xa drug effects, Factor Xa Inhibitors pharmacology, Peptide Hydrolases drug effects, Rivaroxaban pharmacology, Thrombin drug effects
- Abstract
Background: Atrial fibrillation (AF) generates a hypercoagulable state with an increased thrombin generation and raised levels of thrombin-antithrombin complexes, which results in a high risk of stroke and thromboembolism., Aim: To evaluate the anticoagulant effect of rivaroxaban by anti-Xa factor activity and its correlation with thrombin-antithrombin complexes, thrombin generation and prothrombin time in patients newly diagnosed with non-valvular AF., Patients and Methods: Prospective study in patients with indication of anticoagulation. Demographic variables, cardiovascular risk factors, CHA2DS2-VASc and HAS-BLED scores were recorded. Blood samples were taken at baseline, at 3 and 24 hours after the administration of the drug and at 30 days. Rivaroxaban levels, anti-Xa activity, prothrombin time, thrombin generation and plasma levels of thrombin-antithrombin complexes were determined., Results: We studied 20 patients aged 76.3 ± 8.0 years (60% female) with a CHA2DS2-VASc score > 2 points. The anti-Xa factor activity correlated with rivaroxaban plasma levels at 3 hours (r = 0.61, p < 0.01), at 24 hours (r = 0.85, p < 0.01) and at 30 days (r = 0.99, p < 0.01), with prothrombin time at 3 hours (r = -0.86, p = 0.019) and at 30 days (r = -0.63, p = 0.02) and with a sustained decrease in thrombin generation at 30 days of follow-up (r = -0.74, p < 0.01). There was no correlation with thrombin-antithrombin complexes (r = -0.02, p = 0.83)., Conclusions: Rivaroxaban consistently inhibited the mild pro-coagulant state found in newly diagnosed non-valvular AF patients through the first 24 hours and this effect was maintained at 30 days. Plasma levels of the drug correlated with anti-Xa factor activity, thrombin generation and prothrombin time.
- Published
- 2016
- Full Text
- View/download PDF
32. Short fungal fractions of β-1,3 glucans affect platelet activation.
- Author
-
Vancraeyneste H, Charlet R, Guerardel Y, Choteau L, Bauters A, Tardivel M, François N, Dubuquoy L, Soloviev D, Poulain D, Sendid B, and Jawhara S
- Subjects
- Adenosine Triphosphate metabolism, Blood Platelets metabolism, Candida albicans, Fibrinogen drug effects, Fibrinogen metabolism, Fungi chemistry, Humans, Neutrophils, P-Selectin drug effects, P-Selectin metabolism, Phosphorylation, Platelet Glycoprotein GPIIb-IIIa Complex drug effects, Platelet Glycoprotein GPIIb-IIIa Complex metabolism, Protein Kinase C drug effects, Protein Kinase C metabolism, Real-Time Polymerase Chain Reaction, Thrombin drug effects, Thrombin metabolism, Toll-Like Receptor 4 antagonists & inhibitors, Transforming Growth Factor beta1 drug effects, Transforming Growth Factor beta1 metabolism, Up-Regulation, Blood Platelets drug effects, Glucosides pharmacology, Platelet Activation drug effects, Platelet Adhesiveness drug effects, Platelet Aggregation drug effects, Toll-Like Receptor 4 metabolism, beta-Glucans pharmacology
- Abstract
Platelets are capable of binding, aggregating, and internalizing microorganisms, which enhances the elimination of pathogens from the blood. The yeast Candida albicans is a pathobiont causing life-threatening invasive infections. Its cell wall contains β-1,3 glucans that are known to trigger a wide range of host cell activities and to circulate during infection. We studied the effect of β-1,3 glucan fractions (BGFs) consisting of diglucosides (Glc2), tetraglucosides (Glc4), and pentaglucosides (Glc5) on human platelets, their mechanisms of action, and their possible impact on host defenses. The effect of BGFs on the coagulation process was determined by measuring thrombin generation. Platelets pretreated with BGFs were analyzed in terms of activation, receptor expression, aggregation, and adhesion to neutrophils and to C. albicans The results show that BGFs affected the endogenous thrombin potential in a concentration-dependent manner. For platelet activation, BGFs at a low concentration (2 μmol/l) reduced ATP release and prevented the phosphorylation of protein kinase C. BGFs diminished the expression of P-selectin and the activation of αIIbβ3 BGFs decreased platelet aggregation and the interaction between thrombin-stimulated platelets and neutrophils, fibrinogen, and C. albicans GLc5 decreased ATP release and TGF-β1 production in response to TLR4 upregulation in thrombin-stimulated platelets, but TLR4 blockage abolished the effect of BGFs on platelets. This study provides evidence that fungal pentaglucosides modulate platelet activity mediated via TLR4 stimulation and reduce platelet-neutrophil interaction., (Copyright © 2016 the American Physiological Society.)
- Published
- 2016
- Full Text
- View/download PDF
33. Nafamostat mesilate improves function recovery after stroke by inhibiting neuroinflammation in rats.
- Author
-
Li C, Wang J, Fang Y, Liu Y, Chen T, Sun H, Zhou XF, and Liao H
- Subjects
- Animals, Benzamidines, Disease Models, Animal, Guanidines administration & dosage, Inflammasomes drug effects, Male, Microglia drug effects, NF-kappa B drug effects, NLR Family, Pyrin Domain-Containing 3 Protein drug effects, Rats, Rats, Sprague-Dawley, Serine Proteinase Inhibitors administration & dosage, Thrombin drug effects, Behavior, Animal drug effects, Guanidines pharmacology, Infarction, Middle Cerebral Artery drug therapy, Inflammation drug therapy, Recovery of Function drug effects, Serine Proteinase Inhibitors pharmacology
- Abstract
Inflammation plays an important role in stroke pathology, making it a promising target for stroke intervention. Nafamostat mesilate (NM), a wide-spectrum serine protease inhibitor, is commonly used for treating inflammatory diseases, such as pancreatitis. However, its effect on neuroinflammation after stroke was unknown. Hence, the effects of NM on the inflammatory response post stroke were characterized. After transient middle cerebral artery occlusion (tMCAO) in rats, NM reduced the infarct size, improved behavioral functions, decreased the expression of proinflammatory mediators (TNF-α, IL-1β, iNOS and COX-2) in a time-dependent manner and promoted the expression of different anti-inflammatory factors (CD206, TGF-β, IL-10 and IL-4) at different time points. Furthermore, NM could inhibit the expression of proinflammatory mediators and promote anti-inflammatory mediators expression in rat primary microglia following exposure to thrombin combined with oxygen-glucose deprivation (OGD). The immune-modulatory effect of NM might be partly due to its inhibition of the NF-κB signaling pathway and inflammasome activation after tMCAO. In addition, NM significantly inhibited the infiltration of macrophage, neutrophil and T lymphocytes, which was partly mediated by the inhibition of monocyte chemotactic protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Taken together, our results indicated that NM can provide long-term protection of the brain against tMCAO by modulating a broad components of the inflammatory response., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
34. Phthalide Derivatives with Anticoagulation Activities from Angelica sinensis.
- Author
-
Zhang LB, Lv JL, and Liu JW
- Subjects
- Anticoagulants chemistry, Anticoagulants pharmacology, Benzofurans chemistry, Crystallography, X-Ray, Drugs, Chinese Herbal chemistry, Fibrinogen analysis, Fibrinogen drug effects, Molecular Structure, Plant Roots chemistry, Thrombin analysis, Thrombin drug effects, Angelica sinensis chemistry, Anticoagulants isolation & purification, Benzofurans isolation & purification, Benzofurans pharmacology, Drugs, Chinese Herbal isolation & purification, Drugs, Chinese Herbal pharmacology
- Abstract
Two new phthalide derivatives, angesinenolides A and B (1 and 2), were isolated from the roots of Angelica sinensis. Their structures were elucidated using HRMS, NMR, and X-ray crystallographic data. Compound 1 is the first example of a phthalide trimer presumably formed through two [2+2] cycloaddition reactions. Compound 2 is a unique dimeric phthalide with a peroxy bridge between C-3a and C-6. Both phthalides were evaluated for in vitro anticoagulation activities. Compound 1 reduced the level of fibrinogen (FIB). Compound 2 significantly extended thrombin time and activated partial thromboplastin time, as well as markedly reduced the content of FIB.
- Published
- 2016
- Full Text
- View/download PDF
35. Antithrombotic and antiplatelet activities of pelargonidin in vivo and in vitro.
- Author
-
Ku SK, Yoon EK, Lee W, Kwon S, Lee T, and Bae JS
- Subjects
- Animals, Anticoagulants pharmacology, Bleeding Time, Cell Survival drug effects, Cells, Cultured, Factor Xa biosynthesis, Fibrin drug effects, Fibrin metabolism, Humans, Male, Mice, Plasminogen Activator Inhibitor 1 metabolism, Thrombin drug effects, Thrombin metabolism, Tissue Plasminogen Activator metabolism, Anthocyanins pharmacology, Anticoagulants administration & dosage, Blood Coagulation drug effects, Platelet Aggregation drug effects
- Abstract
Pelargonidin is a well-known red pigment found in plants, and has been reported as having important biological activities that are potentially beneficial for human health. However, the possible roles of pelargonidin as an anticoagulant and the underlying mechanism have not yet been elucidated. We tested the effect of pelargonidin and its glucoside-conjugated form, pelargonidin-3-glucoside, on the clotting times, such as activated partial thromboplastin time (aPTT) and prothrombin time (PT), and the activities and productions of thrombin and activated factor X (FXa). Furthermore, the effects of pelargonidin on the fibrin polymerization, platelet aggregation, and the ratio of plasminogen activator inhibitor-1 (PAI-1) to tissue plasminogen activator were determined. Pelargonidin, but not pelargonidin-3-glucoside, prolonged the aPTT and PT, and inhibited the activity and production of thrombin and FXa in human umbilical vein endothelial cells. Furthermore, pelargonidin inhibited thrombin-catalyzed fibrin polymerization and platelet aggregation and elicited anticoagulant effects in mice. In addition, pelargonidin significantly reduced PAI-1 to t-PA ratio. Collectively, these results indicate that the anthocyanin pelargonidin possesses antithrombotic activity, and can be beneficial in preventing thrombus formation, thus improving blood circulation.
- Published
- 2016
- Full Text
- View/download PDF
36. Selective neutralization of the serpin protease nexin-1 by a specific monoclonal antibody.
- Author
-
François D, Venisse L, Brouwers E, Arocas V, Declerck P, and Bouton MC
- Subjects
- Electrophoresis, Polyacrylamide Gel, Fibrinolysin drug effects, Fibrinolysin metabolism, Humans, Serpin E2 metabolism, Thrombin drug effects, Thrombin metabolism, Antibodies, Monoclonal pharmacology, Serpin E2 antagonists & inhibitors
- Published
- 2016
- Full Text
- View/download PDF
37. Pegasparaginase treatment alters thrombin generation by modulating the protein C and S system in acute lymphoblastic leukaemia/lymphoma.
- Author
-
Staddon JH, Smock KJ, Schiffman JD, Fluchel MN, Engel ME, Weyrich AS, and Campbell RA
- Subjects
- Antineoplastic Agents administration & dosage, Asparaginase administration & dosage, Child, Female, Humans, Male, Antineoplastic Agents therapeutic use, Asparaginase therapeutic use, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Protein C metabolism, Protein S metabolism, Thrombin drug effects
- Abstract
Paediatric patients with acute lymphoblastic leukaemia/lymphoma treated with pegasparaginase are at an increased risk of thrombosis. We evaluated changes in thrombin generation in the presence and absence of thrombomodulin using paired plasma samples collected from paediatric patients treated with pegasparaginase. Postpegasparaginase samples were significantly less sensitive to reductions in thrombin generation in the presence of thrombomodulin compared with prepegasparaginase, suggesting reduced protein C and S activity. This corresponded to a significant decrease in protein C and protein S antigen. Alterations in the protein C and S pathway may contribute to the increased risk of thrombosis in patients treated with pegasparaginase.
- Published
- 2015
- Full Text
- View/download PDF
38. Modulation of the Coagulation Cascade Using Aptamers.
- Author
-
Woodruff RS and Sullenger BA
- Subjects
- Aptamers, Nucleotide pharmacology, Blood Coagulation genetics, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Female, Humans, Male, Prothrombin drug effects, Prothrombin metabolism, Sensitivity and Specificity, Serine Endopeptidases drug effects, Serine Endopeptidases metabolism, Thrombin drug effects, Thrombin metabolism, Aptamers, Nucleotide therapeutic use, Blood Coagulation drug effects, Molecular Targeted Therapy methods
- Abstract
As a novel class of therapeutics, aptamers, or nucleic acid ligands, have garnered clinical interest because of the ease of isolating a highly specific aptamer against a wide range of targets, their chemical flexibility and synthesis, and their inherent ability to have their function reversed. The following review details the development and molecular mechanisms of aptamers targeting specific proteases in the coagulation cascade. The ability of these anticoagulant aptamers to bind to and inhibit exosite function rather than binding within the active site highlights the importance of exosites in blocking protein function. As both exosite inhibitors and reversible agents, the use of aptamers is a promising strategy for future therapeutics., (© 2015 American Heart Association, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
39. INR vs. thrombin generation assays for guiding VKA reversal: a retrospective comparison.
- Author
-
Herpers R, van Rossum AP, van Beem RT, Michel WM, Strijbis VJ, Strengers PF, Castel A, and Brinkman HJ
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Retrospective Studies, Thrombin drug effects, Thrombin Time, Anticoagulants pharmacology, Blood Coagulation Tests, International Normalized Ratio, Thrombin biosynthesis, Vitamin K antagonists & inhibitors
- Abstract
Background: Prothrombin complex concentrate (PCC) is used to reverse vitamin K antagonist (VKA)-induced anticoagulation. Prothrombin time-derived international normalized ratio (INR) measurements are widely used in determining the required PCC dose, but this approach requires reappraisal. The aim of the present study was to determine the added value of the thrombin generation assay (TGA) compared with the INR in guidance of VKA reversal by PCC., Methods: In an open, observational study, INR and TGA measurements were carried out on plasma samples from phenprocoumon-treated patients receiving VKA reversal. Following both analytical methods, PCC dosing correlates were calculated and compared retrospectively. Alternatively, in vitro PCC spiking experiments were performed., Results: As expected, an exponential relationship between PCC dose and INR was found. For the TGA parameters peak thrombin and endogenous thrombin potential (ETP), however, this relationship was found to be linear throughout the full therapeutic range. Additional computational analysis showed a positive correlation (r²=0.7) between the initial INR and PCC dose required for a target INR of 2.1, which was completely lost at a lower target INR. In contrast, a positive correlation (r²=0.8) between initial ETP as well as peak height and PCC dose required to obtain parameter normalization was found. These correlates appeared useful for calculating PCC dose., Conclusions: Our results support the current debate questioning the rationale for the use of the INR in the management of anticoagulation by VKA. Compared with INR, TGA-based calculations may enable a more accurate PCC dosing regimen for patients requiring VKA reversal.
- Published
- 2015
- Full Text
- View/download PDF
40. Mass spectrometry identification of potential mediators of progestin-only contraceptive-induced abnormal uterine bleeding in human endometrial stromal cells.
- Author
-
Shapiro JP, Basar M, Kayisli UA, Guzeloglu-Kayisli O, Joseph Huang S, Suarez AA, Ozer HG, Schatz F, and Lockwood CJ
- Subjects
- Cells, Cultured, Contraceptive Agents, Female administration & dosage, Desogestrel administration & dosage, Desogestrel adverse effects, Endometrium cytology, Estradiol administration & dosage, Estradiol adverse effects, Female, Glycoproteins drug effects, Humans, Hypoxia chemically induced, Medroxyprogesterone Acetate administration & dosage, Medroxyprogesterone Acetate adverse effects, Progestins administration & dosage, Thrombin drug effects, Contraceptive Agents, Female adverse effects, Mass Spectrometry, Progestins adverse effects, Stromal Cells drug effects, Uterine Hemorrhage chemically induced
- Abstract
Objective: Thrombin and hypoxia each target human endometrial stromal cells (HESCs) to mediate long-acting progestin-only contraceptive (LAPC)-induced abnormal uterine bleeding (AUB). Thus, the secretome resulting from treatment of primary cultures of HESCs with thrombin or hypoxia was screened by mass spectrometry (MS) to detect potential protein mediators that lead to AUB., Study Design: Cultured HESCs were primed with estradiol±medroxyprogesterone acetate (MPA) or etonogestrel (ETO), the respective progestins in MPA-injected and ETO-implanted LAPCs, and then treated by incubation with thrombin or under hypoxia. Collected conditioned medium supernatants were used for protein identification and quantitation of potential AUB mediators by liquid chromatography combined with tandem mass spectrometry analysis. Microarray analysis of parallel cultures and immunostaining of endometrial biopsies of LAPC users vs. nonusers corroborated MS results., Results: MS identified several proteins displaying changes in expression levels from either thrombin or hypoxia treatments that are integral to angiogenesis or extracellular matrix formation. Several MS-identified proteins were confirmed by mRNA microarray analysis. Overexpressed stanniocalcin-1 (STC-1) was observed in endometrium of LAPC users. Unlike controls, all LAPC users displayed endometrial tubal metaplasia (ETM)., Conclusions: MS analysis identified many proteins that can affect angiogenesis or vessel integrity, thereby contributing to AUB. Confirmation of STC-1 overexpression in LAPC users and microarray data supports the validity of the MS data and suggests STC-1 involvement in AUB. The discovery of ETM in LAPC users indicates that LAPC-related side effects extend beyond AUB. The results presented here demonstrate a complex biological response to LAPC use., Implications: MS identified several HESC secreted proteins deregulated by thrombin and hypoxia that may mediate LAPC-induced AUB. The revelation of overexpressed STC-1 by combined in vivo and in vitro observations identifies a potential target for future studies to prevent or minimize LAPC-induced AUB., (Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
41. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
- Author
-
Morishima Y and Kamisato C
- Subjects
- Blood Coagulation drug effects, Humans, Platelet-Rich Plasma drug effects, Blood Coagulation Tests methods, Factor Xa Inhibitors pharmacology, Partial Thromboplastin Time, Prothrombin Time, Pyridines pharmacology, Thiazoles pharmacology, Thrombin drug effects
- Abstract
Objectives: Edoxaban, an oral direct factor Xa inhibitor, does not require routine monitoring. However, assessment of the anticoagulant effects may be required in certain situations., Methods: We investigated the effects of edoxaban on prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin generation using human platelet-poor plasma (PPP) or platelet-rich plasma (PRP)., Results: Edoxaban concentration-dependently prolonged PT and aPTT. There was a considerable variation in the magnitude of PT prolongation among the reagents used. The variability in aPTT prolongation among the reagents was smaller than that of PT. Edoxaban concentration-dependently inhibited thrombin generation, with a more potent effect seen in PPP than in PRP. Thrombin generation assay was three times more sensitive to edoxaban than PT and aPTT., Conclusions: PT had disadvantages of a large variability among different PT reagents. aPTT could be used as a conventional and convenient test with a smaller variation among reagents. Thrombin generation was the most sensitive assay., (Copyright© by the American Society for Clinical Pathology.)
- Published
- 2015
- Full Text
- View/download PDF
42. Hypercoagulability following major partial liver resection - detected by thrombomodulin-modified thrombin generation testing.
- Author
-
Potze W, Alkozai EM, Adelmeijer J, Porte RJ, and Lisman T
- Subjects
- Adult, Aged, Blood Coagulation Factors metabolism, Factor VIII, Female, Humans, Male, Middle Aged, Pancreatectomy adverse effects, Thrombin drug effects, Blood Coagulation Tests, Hepatectomy adverse effects, Thrombin metabolism, Thrombomodulin agonists, Thrombophilia diagnosis
- Abstract
Background: Conventional coagulation tests are frequently prolonged after liver surgery, suggesting a post-operative hypocoagulability. However, these tests are unreliable for assessment of the haemostatic status in these patients. In contrast, thrombin generation testing measures the true balance between pro- and anti-coagulant factors., Aim: To study the perioperative coagulation status in patients undergoing hemi-hepatectomy using thrombin generation assays., Methods: We examined thrombin generation profiles in serial plasma samples taken from seventeen patients undergoing right hemi-hepatectomy. Results were compared to ten patients undergoing pancreatic resection and twenty-four healthy volunteers. In addition, we measured conventional coagulation tests and plasma levels of several haemostatic proteins., Results: Following liver resection, the endogenous thrombin potential (ETP) slightly decreased until post-operative day 7. However, in the presence of thrombomodulin, the ETP increased [from 542 nM*min (417-694) at baseline to 845 nM*min (789-1050) on post-operative day 3] to values higher than that in healthy subjects (558 nM*min (390-680); P < 0.001), which contrasts with substantially prolonged PT levels. Normal to decreased thrombin generation was observed following pancreatic resection. Thrombin generation was only slightly affected by thrombomodulin after hemi-hepatectomy, while thrombin generation in healthy subjects decreased profoundly upon addition of thrombomodulin. This hypercoagulability following liver resection may be explained by decreased levels of protein C, S, and antithrombin and by elevated levels of factor VIII., Conclusions: Thrombin generation in the presence of thrombomodulin revealed hypercoagulability in patients following liver resection. These results support the recently advocated restrictive use of plasma during liver resection and the exploration of more extensive use of post-operative thrombosis prophylaxis., (© 2014 John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
43. Production of recombinant streptokinase from Streptococcus pyogenes isolate and its potential for thrombolytic therapy.
- Author
-
Assiri AS, El-Gamal BA, Hafez EE, and Haidara MA
- Subjects
- Fibrin Clot Lysis Time, Genetic Vectors, Humans, Pharyngitis microbiology, Recombinant Proteins biosynthesis, Streptococcal Infections microbiology, Streptococcus pyogenes isolation & purification, Streptokinase genetics, Streptokinase pharmacology, Thrombin drug effects, Fibrinolytic Agents pharmacology, Pichia, Streptococcus pyogenes genetics, Streptokinase biosynthesis, Thrombolytic Therapy
- Abstract
Objectives: To produce an effective recombinant streptokinase (rSK) from pathogenic Streptococcus pyogenes isolate in yeast, and evaluate its potential for thrombolytic therapy., Methods: This study was conducted from November 2012 to December 2013 at King Khalid University, Abha, Kingdom of Saudi Arabia (KSA). Throat swabs collected from 45 pharyngitis patients in Asser Central Hospital, Abha, KSA were used to isolate Streptococcus pyogenes. The bacterial DNA was used for amplification of the streptokinase gene (1200 bp). The gene was cloned and in vitro transcribed in an eukaryotic expression vector that was transformed into yeast Pichia pastoris SMD1168, and the rSK protein was purified and tested for its thrombolytic activity., Results: The Streptococcus pyogenes strain was isolated and its DNA nucleotide sequence revealed similarity to other Streptococcus pyogenes in the Gene bank. Sequencing of the amplified gene based on DNA nucleotide sequence revealed a SK gene closely related to other SK genes in the Gene bank. However, based on deduced amino acids sequence, the gene formed a separate cluster different from clusters formed by other examined genes, suggesting a new bacterial isolate and accordingly a new gene. The purified protein showed 82% clot lysis compared to a commercial SK (81%) at an enzyme concentration of 2000 U/ml., Conclusion: The present yeast rSK showed similar thrombolytic activity in vitro as that of a commercial SK, suggesting its potential for thrombolytic therapy and large scale production.
- Published
- 2014
44. Hormone therapy and hemostasis among postmenopausal women: a review.
- Author
-
Canonico M
- Subjects
- Administration, Cutaneous, Administration, Oral, Dose-Response Relationship, Drug, Estrogen Replacement Therapy methods, Estrogens administration & dosage, Female, Humans, Middle Aged, Postmenopause, Progestins administration & dosage, Risk Assessment, Thrombin drug effects, Venous Thromboembolism metabolism, Estrogen Replacement Therapy adverse effects, Estrogens adverse effects, Hemostasis drug effects, Progestins adverse effects, Venous Thromboembolism chemically induced
- Abstract
Objective: Postmenopausal hormone therapy (HT), which consists of exogenous estrogens with or without combined progestogens, remains the most effective treatment of climacteric symptoms. Depending on its characteristics, it may nevertheless increase the risk of venous thromboembolism, and its effects on hemostasis have been studied for several decades. The aim of this review was to summarize current knowledge on the effects of HT on hemostasis, taking into account the route of estrogen administration, the daily dose and chemical structure of estrogens, and the pharmacologic class of progestogens., Methods: Data from randomized controlled trials that included a control group (either placebo or no treatment) were selected, and analysis was conducted on different generations of biomarkers., Results: Overall, studies showed a hemostasis imbalance among oral estrogen users with a decrease in coagulation inhibitors and an increase in markers of activation coagulation, leading to global enhanced thrombin generation. By contrast, transdermal estrogen use was associated with less change in hemostasis variables and did not activate coagulation and fibrinolysis. No clear difference in HT effects on hemostasis was highlighted between daily doses of estrogens, between estrogen compounds, and between pharmacologic classes of progestogens., Conclusions: Changes in hemostasis are in accordance with clinical results showing an increased thrombotic risk with oral--but not transdermal--estrogen use.
- Published
- 2014
- Full Text
- View/download PDF
45. Prediction of thrombin and factor xa inhibitory activity with associative neural networks.
- Author
-
Kovalishyn V, Tanchuk V, Kopernyk I, Prokopenko V, and Metelytsia L
- Subjects
- Antithrombins chemistry, Factor Xa drug effects, Models, Molecular, Neural Networks, Computer, Quantitative Structure-Activity Relationship, Regression Analysis, Thrombin drug effects, Antithrombins pharmacology, Drug Design, Factor Xa Inhibitors pharmacology
- Abstract
Quantitative structure-activity relationship studies on a series of selective inhibitors of thrombin and factor Xa were performed by using Associative Neural Network. To overcome the problem of overfitting due to descriptor selection, 5-fold cross-validation with variable selection in each step of the analysis was performed. The predictive ability of the models was tested through leave-one-out cross-validation, giving a Q2=0.74-0.87 for regression models. Predictions for the external evaluation sets obtained accuracies in the range of 0.71-0.82 for regressions. The proposed models can be potential tools for finding new drug candidates.
- Published
- 2014
- Full Text
- View/download PDF
46. Direct thrombin inhibitors and factor xa inhibitors can influence the diluted prothrombin time used as the initial screen for lupus anticoagulant.
- Author
-
Olah Z, Szarvas M, Bereczky Z, Kerenyi A, Kappelmayer J, and Boda Z
- Subjects
- Anticoagulants chemistry, Antithrombins chemistry, Arginine analogs & derivatives, Chondroitin Sulfates chemistry, Chondroitin Sulfates pharmacology, Dermatan Sulfate chemistry, Dermatan Sulfate pharmacology, Enoxaparin chemistry, Enoxaparin pharmacology, False Positive Reactions, Fondaparinux, Heparitin Sulfate chemistry, Heparitin Sulfate pharmacology, Hirudins chemistry, Hirudins pharmacology, Humans, Pipecolic Acids chemistry, Pipecolic Acids pharmacology, Polysaccharides chemistry, Polysaccharides pharmacology, Prothrombin Time, Recombinant Proteins chemistry, Recombinant Proteins pharmacology, Sulfonamides, Thrombin chemistry, Anticoagulants pharmacology, Antithrombins pharmacology, Factor Xa Inhibitors, Lupus Coagulation Inhibitor blood, Mass Screening methods, Thrombin drug effects
- Abstract
Context: Lupus anticoagulant (LA) is a heterogeneous group of antiphospholipid antibodies. Among others, diluted prothrombin time (dPT) is a sensitive screening test for LA; however, the interpretation of LA tests is difficult in patients treated with anticoagulants. The effect of different types of anticoagulants on the result of LA tests, particularly on dPT, has not been studied extensively., Objective: To determine whether the direct thrombin inhibitors lepirudin and argatroban and the predominantly factor Xa inhibitors enoxaparin, danaparoid, and fondaparinux could interfere with LA screening based on dPT., Design: Each drug was added to normal and LA-positive plasmas in clinically relevant concentrations. Each sample was tested for dPT. Samples with factor Xa inhibitors were investigated before and after addition of heparinase. Mixing and confirmatory tests for LA were not performed., Results: In the presence of lepirudin or argatroban, dPT increased notably and the dPT ratio exceeded the cutoff value even at subtherapeutic concentrations resulting in false positivity. With increasing factor Xa inhibitor concentrations, a linear increase of dPT ratios and false-positive results were also demonstrated. Although heparinase could almost completely neutralize the anti-Xa effect of all investigated factor Xa inhibitors, dPT ratio returned to the basal level only in case of enoxaparin., Conclusions: Here we provide evidence that both the direct thrombin and indirect factor Xa inhibitors influence dPT assay for LA, causing false positivity. This should be considered when interpreting LA results during anticoagulant therapy. However, dPT seems to be a reliable test for LA screening under enoxaparin therapy after neutralization by heparinase.
- Published
- 2013
- Full Text
- View/download PDF
47. Acute CO poisoning is associated with impaired fibrinolysis and increased thrombin generation.
- Author
-
Gawlikowski T, Gomolka E, Piekoszewski W, Jawień W, and Undas A
- Subjects
- Acute Disease, Adult, Blood Coagulation Tests, Carbon Monoxide Poisoning blood, Female, Fibrin metabolism, Fibrinolysis physiology, Humans, Male, Peptide Fragments blood, Permeability, Plasminogen Activator Inhibitor 1 blood, Prothrombin, Thrombin biosynthesis, Tissue Plasminogen Activator blood, Carbon Monoxide Poisoning pathology, Fibrinolysis drug effects, Thrombin drug effects
- Abstract
Carbon monoxide (CO) poisoning is a leading cause of unintentional poisoning deaths in many countries. In ex vivo studies, CO released from carbon monoxide-releasing molecules has been shown to attenuate fibrinolysis via increased alpha-2-antiplasmin activity. Hypofibrinolysis is associated with coronary ischaemia, which is also commonly observed in CO poisoning. We examined fibrin clot properties in acutely poisoned CO patients. Ex vivo plasma fibrin clot permeability, turbidimetry and efficiency of fibrinolysis were investigated in 48 patients and controls matched for age and sex. CO-poisoned patients had 11.6% longer clot lysis time than the controls (p < 0.0001). No intergroup differences in clot permeability or turbidimetric variables were observed. Plasma tissue-type plasminogen antigen (tPA), plasminogen activator inhibitor-1 (PAI-1) antigen and activity and F1.2 prothrombin fragments were higher in the patients than in the controls (all p < 0.0001). Plasma tPA activity was lower in the CO-poisoned group. Multiple linear regression showed that a thrombin generation marker, F1.2, is the strongest predictor of clot lysis time, followed by PAI-1 activity and carboxyhaemoglobin levels. In conclusion, this report is the first to demonstrate that acute CO poisoning in human beings is linked to increased thrombin generation and impaired fibrinolysis, which might contribute to ischaemic complications., (© 2012 Nordic Pharmacological Society. Published by Blackwell Publishing Ltd.)
- Published
- 2013
- Full Text
- View/download PDF
48. Acidosis, magnesium and acetylsalicylic acid: effects on thrombin.
- Author
-
Borisevich N, Loznikova S, Sukhodola A, Halets I, Bryszewska M, and Shcharbin D
- Subjects
- Humans, Hydrogen-Ion Concentration, Kinetics, Luminescent Measurements, Magnesium Sulfate pharmacology, Platelet Aggregation drug effects, Sodium Chloride pharmacology, Temperature, Time Factors, Tryptophan chemistry, Acidosis metabolism, Aspirin pharmacology, Magnesium pharmacology, Thrombin drug effects
- Abstract
Thrombin, an enzyme from the hydrolase family, is the main component of the blood coagulation system. In ischemic stroke it acts as a serine protease that converts soluble fibrinogen into insoluble strands of fibrin forming blood clots in the brain. It has been found to phosphoresce at room temperature in the millisecond and microsecond ranges. The phosphorescence of thrombin was studied under physiological conditions, in acidosis (decrease of pH from 8.0 to 5.0) and on the addition of salts (magnesium sulfate and sodium chloride) and of acetylsalicylic acid, and its connection with thrombin function is discussed. Acidosis significantly increased the internal dynamics of thrombin. We propose that lactate-acidosis plays a protective role in stroke, preventing the formation of clots. The addition of NaCl and MgSO(4) in different concentrations increased the internal dynamics of thrombin. Also, the addition of MgSO(4) decreased thrombin-induced platelet aggregation. However, magnesium sulfate and acetylsalicylic acid in the therapeutic concentrations used for treatment of ischemic stroke had no effect on thrombin internal dynamics. The data obtained will help to elucidate the conformational stability of thrombin under conditions modulating lactate-acidosis and in the presence of magnesium sulfate., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
49. Molecular cloning and antifibrinolytic activity of a serine protease inhibitor from bumblebee (Bombus terrestris) venom.
- Author
-
Qiu Y, Lee KS, Choo YM, Kong D, Yoon HJ, and Jin BR
- Subjects
- Amino Acid Sequence, Animals, Antifibrinolytic Agents chemistry, Baculoviridae genetics, Base Sequence, Bee Venoms genetics, Cloning, Molecular, Drug Combinations, Electrophoretic Mobility Shift Assay methods, Fibrinolysin antagonists & inhibitors, Fibrinolysin pharmacology, Gene Expression, Insect Proteins genetics, Insect Proteins pharmacology, Insecta, Molecular Sequence Data, Recombinant Proteins, Sequence Alignment, Serine Proteinase Inhibitors chemistry, Thrombin drug effects, Antifibrinolytic Agents pharmacology, Bee Venoms metabolism, Bees physiology, Serine Proteinase Inhibitors genetics, Serine Proteinase Inhibitors pharmacology
- Abstract
Bumblebee (Bombus spp.) venom contains a variety of components, including bombolitin, phospholipase A(2) (PLA(2)), serine proteases, and serine protease inhibitors. In this study, we identified a bumblebee (Bombus terrestris) venom serine protease inhibitor (Bt-KTI) that acts as a plasmin inhibitor. Bt-KTI consists of a 58-amino acid mature peptide that displays features consistent with snake venom Kunitz-type inhibitors, including six conserved cysteine residues and a P1 site. Recombinant Bt-KTI was expressed as a 6.5-kDa peptide in baculovirus-infected insect cells. The recombinant peptide demonstrated properties similar to Kunitz-type trypsin inhibitors. Bt-KTI showed no detectable inhibitory effects on factor Xa, thrombin, or tissue plasminogen activator; however, Bt-KTI strongly inhibited plasmin, indicating that it acts as an antifibrinolytic agent. These findings demonstrate the antifibrinolytic role of Bt-KTI as a plasmin inhibitor., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
50. Bioactivity of enoxaparin in critically ill patients with normal renal function.
- Author
-
Gouya G, Palkovits S, Kapiotis S, Madl C, Locker G, Stella A, Wolzt M, and Heinz G
- Subjects
- Adult, Aged, Anticoagulants pharmacokinetics, Case-Control Studies, Critical Illness, Enoxaparin pharmacokinetics, Female, Humans, Injections, Subcutaneous, Intensive Care Units, Kidney Function Tests, Male, Middle Aged, Models, Biological, Prospective Studies, Thrombin drug effects, Thrombin metabolism, Thrombosis drug therapy, Time Factors, Anticoagulants pharmacology, Enoxaparin pharmacology, Factor Xa Inhibitors, Venous Thromboembolism prevention & control
- Abstract
What Is Already Known About This Subject: Venous thromboembolism is a frequent complication in critically ill patients that has a negative impact on patient outcomes. Critically ill patients have significantly lower plasma anti-factor-Xa activity levels compared with control patients after administration of subcutaneous heparin. The clinical relevance of the different anti-factor-Xa levels after prophylactic doses of low molecular weight heparin (LMWH) in critically ill patients is not completely understood., What This Study Adds: The standard dose of 40 mg enoxaparin led to a significant increase in anti-FXa levels in this selected cohort of ICU patients with normal renal function. This study found only subtle pharmacokinetic differences, but a comparable pharmacodynamic action, after enoxaparin administration in critically ill and normal medical ward patients. Thrombin generation with TGA RC-low and TGARC-high reagents was significantly reduced in ICU and normal ward patients after receiving LMWH. Both readouts appear equally useful for estimating the pharmacodynamics of enoxaparin. The ex vivo model of thrombosis was used for the first time in patients to evaluate the anti-thrombotic activity of LMWH. This method did not show any difference in thrombus formation after administration of enoxaparin in the individual group of patients., Aim: In critically ill patients, reduced anti-FXa plasma activity following subcutaneous administration of enoxaparin or nadroparin has been described. In this study, we aimed to investigate the bioactivity of enoxaparin in critically ill patients and controls., Methods: A prospective, controlled, open label study was performed on a medical intensive care unit (ICU) and a general medical ward. Fifteen ICU patients (male = 12, median age 52 years [IQR 40-65], with a median Simplified Acute Physiology Score of 30 [IQR 18-52]) and sex- and age-matched medical ward patients were included. The anti-FXa plasma activity was measured after a single subcutaneous dose of40 mg enoxaparin. The thrombus size of a clot formed in an ex vivo perfusion chamber and endogenous thrombin potential (ETP) were measured., Results: The anti-FXa plasma activity increased significantly after enoxaparin administration, with peak levels at 3 h after treatment, but was comparable between the ICU and medical ward groups (median 0.16 IU ml-1 [IQR 0-0.22 IU ml-1] vs. 0.2 IU ml-1 [IQR 0.15-0.27 IU ml-1],respectively, P = 0.13). The area under the anti-FXa activity curve from 0–12 h was similar between the groups (median 0.97 IU ml-1 h [IQR0.59-2.1] and 1.48 IU ml-1 h1 [IQR 0.83-1.62], P = 0.42 for the ICU group compared with the control group, respectively). The ETP was lower in the ICU group (P < 0.05) at baseline, but it was comparable at 3 h between the groups. Thrombus size decreased at 3 h compared with pre-dose (P = 0.029) and was not different between the groups., Conclusion: Similar bioactivity was achieved with a standard dose of subcutaneous enoxaparin in this selected cohort of ICU and general ward patients with normal renal function.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.